Alzheimer's DiseaseNCT03942341
Sleep in Adults With Down Syndrome and Alzheimer's Disease
An observational study of Alzheimer's Disease and Obstructive Sleep Apnea, run by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau at 1 site in Spain.
Trial summary
RATIONALE of the project. Adults with Down syndrome (DS) present severe sleep disorders that are under recognized by caregivers. Aging in DS population increases the prevalence of both Obstructive Sleep Apnea (OSA) and Alzheimer´s disease (AD) dementia at much higher rates than in the general population. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Alzheimer's Disease, Obstructive Sleep Apnea, Sleep Disturbances
- How many people
- 90 participants
- Where
- 1 siteSpain
- Study dates
- 8 May 2019to Dec 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All participants will be included after obtaining a written informed consent approved by the ethics committee. A total of 90 DS subjects with AD dementia of both sexes and good general condition will be included. The presence of a family member will be required as well as a sufficient visual and hearing acuity.
Who may be able to join
- Subjects of both sexes with ages over 18 years old with DS.
- Subjects will have to be able to understand and accept the study procedures and sign an informed consent (patient and or guardian).
- Only subjects with mild and moderate mental retardation according to ICD-10criteria (IQ scores> 34).
- Subjects with dementia: subjects with acquired cognitive impairment (assessed by longitudinal neuropsychological tests and/or anamnesis to the family). Absence of comorbid psychiatric disorders (major depressive disorder, bipolar disorder, schizophrenia, autism or behavioral disorders).
Who cannot join
- Don't meet Inclusion Criteria
- Severe mental retardation
- History of conditions that could affect brain structure or function, such as stroke or traumatic brain injury
- Patients in treatment with CPAP
- New psychoactive drugs in the last three months preceding the survey.
Trial locations and contacts
1 site in 1 country.
Spain1 site, 1 recruiting
- Recruiting
Hospital de la Santa Creu i Sant Pau
Barcelona, 08025
Sandra Gimenez, MD, PhD, +34935537324, sgimenez@santpau.cat
About this study
Official title: The Impact of Alzheimer's Disease on Sleep in Adults With Down Syndrome
RATIONALE of the project. Adults with Down syndrome (DS) present severe sleep disorders that are under recognized by caregivers. Aging in DS population increases the prevalence of both Obstructive Sleep Apnea (OSA) and Alzheimer´s disease (AD) dementia at much higher rates than in the general population. AD increases the risk of sleep disturbances and OSA, which in turn worsen cognitive performance and behavioral function.
Our hypothesis is that adults with DS and AD dementia will present a higher prevalence of sleep disorders (sleep disruption, sleep circadian disorders and OSA) than in DS without dementia.
Read more
There are no data evaluating nocturnal sleep in adults with DS with AD dementia.
The main objective is to evaluate the prevalence of sleep disturbances in adult subjects with DS and AD dementia, by means of subjective and objectives sleep measures.
Read the detailed description
Aims To characterize and determine the prevalence of sleep disorders and sleep wake pattern in a large community-based sample of adult subjects with DS and AD dementia and to correlate the results with clinical, cognitive and behavioral features.
OBJECTIVES:
The general objective is to evaluate the impact of AD dementia on sleep in adults with DS.
- By evaluating the frequency of sleep problems in demented adults with DS through:
- Nocturnal sleep by polysomnography (PSG)
- Subjective sleep quality (Pittsburg) and daytime Somnolence (Epworth)
- Sleep-wake pattern by actimetry
- By analyzing the association between sleep problems and both age and body mass index (BMI)
- By analyzing the impact of sleep problems on:
- Daytime Somnolence (Epworth, actigraphy)
- Diurnal Behavioural disturbances
- Neurophysiological performance The secondary objective is to compare the sleep data of the DS patients with AD dementia with our sleep data of DS patients without dementia. The project is the continuation of our sleep research work in adults with DS. We have performed a community-based cross-sectional study in 54 adults with DS by means of objective and subjective measures, and we found a high prevalence of sleep disorders (Giménez, 2018). In this study, 6 DS patients had AD dementia. Although the sample was very small, our results show that the symptomatic AD-DS group presented a higher apnea hypopnea index (AHI), higher oxygen desaturations (ODI-3%), and higher respiratory arousal index compared to the non demented DS group. The DS group with dementia had also worse sleep efficiency and higher sleep fragmentation. METHODS: Muliticenter sleep study. Cross-sectional analytical study. The study duration is 24 months. Participants: 90 subjects with DS and AD. Only subjects with mild and moderate mental retardation will be included. Variables and method of collection:
- Neurological evaluation: Standard visit in which medical and neurological past medical history will be reviewed to apply the inclusion and exclusion criteria.
- Neuropsychological evaluation: The neuropsychological battery will be administered by neuropsychologists with experience in the evaluation of DS subjects. The study includes neuropsychological tests that have proven to be sensitive to detect cognitive impairment and is based, in part, from the recommendations of the "Working Group for the Establishment of Criteria for the Diagnosis of Dementia in Individuals with Intellectual Disability." The complete battery has an approximate length of 90 min and consists in:
- Functional, daily living activities and neuropsychiatric scales.
- Estimated Intelligence Quotient (IQ): Kaufman Brief Intelligence Test (K-BIT).
- Global cognition battery adapted to Intellectual Disabilities: CAMDEX-DS, including the structured interview CAMDEX-DS and the cognitive battery CAMCOG-DS.
- Memory: The Cued Recall Test (CRT) adapted version (Deveny, 2002).
- Executive function: Cats and dogs test (adaptation of Day-Night Stroop), to measure inhibition capacity and backward digits.
- Attention: cancellation test.
- Language: semantic fluency test (animals), 30 items from the Boston Naming Test (BNT).
- Sleep evaluation: All participants will undergo a full sleep evaluation. This includes a sleep interview with a sleep specialist, and a subjective and objective evaluation of nocturnal sleep and the circadian sleep-wake pattern. Nocturnal sleep will be objectively studied by full video PSG and Sleep/wake pattern will be collected via sleep diaries and actigraphy. c.1. Objective sleep measures: Polysomnography (PSG). Sleep recordings will be performed in individual, sound-attenuated, temperature-regulated rooms in sleep units in all groups. Participants will be continuously supervised by qualified technical staff and recorded on video/audio with the use of an infrared camera. PSGs will start at their median bedtime as defined by the prospective diary collection, with a recording time of 8 hours. The morning after the PSG nights, all subjects will complete a subjective questionnaire about their sleep quality in the laboratory. We will compare this questionnaire with their usual reported sleep quality at home. All-night video PSG-recordings include: 1) 19 EEG- channels referenced to averaged mastoid electrodes (A1-A2) according to the international 10-20 system; 2) 2 electroculographic channels; and 3) 4 surface electromyographic channels: 2 from the mentalis, one from the right anterior tibialis and one from the left anterior tibialis in lower limbs; and 4) 6 channels to monitor respiratory function: one for oximetry, 2 for oro-nasal airflow using a thermistor and nasal-cannula, 2 to record thoraco-abdominal movements by inductance plethysmography, and a microphone at the suprasternal notch to detect snoring. Sleep stages will be visually scored for 30-s epochs according to the guidelines of the American Academy of Sleep Medicine (AASM). Scoring will be performed by an experienced sleep technologist and later reviewed by an accredited sleep specialist. Arousals will be defined using AASM criteria. Respiratory variables will include the apnea/hypopnea index (AHI), defined as the sum of all apneas (> 90% reduction in airflow for >10 seconds) and all hypopneas (airflow reduction greater than 30% for at 11 least 10 seconds with an oxygen saturation decrease of approximately 3% or a cortical awakening) per hour of sleep, and mean oxygen saturation during the night (Sp02). Periodic leg movements and abnormal REM sleep behavior disorder will be defined according to the International Criteria of Sleep Disorders. c.2. Actigraphy: During the week before the PSG, participants will wear an actigraph in the non-dominant arm, a method of monitoring human rest/activity cycles. Variables obtained by actimetry will be analysed in two groups:
- Activity analysis: variables describing level of activity and light during 24 hours and during all period. Includes average of daily activity during all period, maximum activity times and variance.
- Sleep analysis: to asses sleep variables derived from actigraphy, bedtime and awake time would be need to know from each subject. These information will be collected through event marker system of the actimeter and from sleep diaries recording. c.3. Subjective Sleep Measures (assessed by caregiver): All participants will have a notebook that includes subjective sleep questionnaires and sleep diaries to be completed by the caregivers. Sleep questionnaires will include the following scales: the Pittsburgh Sleep Quality Index (PSQI) to assess patients' self-reports of sleep quality; the Epworth Sleepiness Scale (ESS) to evaluate somnolence (with a modification of the last question about the DS person as a passenger in a car while stopped for a few minutes in traffic); and the Berlin Questionnaire (BQ) to identify subjects at risk for the sleep apnea syndrome Sleep diary is a daily report of sleep and waking activities over 24-hour periods. The sleep diary reports: bedtime, wake time, how much time taken to fall asleep, how much time spent awake after sleep onset. STATISTICAL ANALYSIS: Statistical analyses will be performed using SPSS v23 software. Demographics and sleep scores will be compared between groups by means of t tests. The statistical threshold is set at 0.05. To assess the differences between the various sleep techniques performed in DS participants, general lineal models (GLM) with one within-subject factor (techniques, 3 levels) will be applied separately to each sleep variable. For all variables, results will be pair-compared by means of the t-test. Greenhouse-Geisser correction will be used. The Pearson correlation will be applied to evaluate the relationship between sleep variables. STUDY LIMITATIONS The main foreseen limitation for this study it the heterogeneity of the DS population. To try to overcome this difficulty and to facilitate the feasibility of the study, only subjects with mild or mild-moderate mental retardation will be selected. ETHICAL ISSUES The study will be carried out in strict accordance with international ethical guidelines for medical research in humans. Researchers are responsible for ensuring that the study is conducted in accordance with standards contained in the Declaration of Helsinki and local regulation. All participants will be included after obtaining a written informed consent (the family member's consent will also be obtained). Before including any subject in the study, the investigator will inform the participant of the objectives, methods and potential risks of the study or any inconvenience this may cause. The studies that will be performed in this project are not part of the routine evaluation of subjects with DS and they have an interest only from a research point of view. To preserve the confidentiality of information, data pertaining to this study will not be included in the conventional medical history, but in a separate file in a protected location.
- Keywords
- Down syndrome, Alzheimer's disease, obstructive sleep apnea, Polysomnography
- Medical subject headings
- Alzheimer Disease, Sleep Apnea, Obstructive, Parasomnias, Down Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Adult subjects with Down syndrome and Alzheimer Disease | Patients will be included from the 6 centers of the Horizon 21 european consortium. Horizon 21 consortium consists of DS cohorts from Spain (the Down Alzheimer Barcelona Neuroimaging Initiative -DABNI). France (the TriAl 21 at Jérôme Lejeune Institute in Paris), the UK (The LonDowns consortium and Dementia in Down's Syndrome (DiDS) in Cambridge), the Netherlands (the Rotterdam DS cohort) and Germany (AD21 in Munich), with a combined total of more than 1,000 older participants with DS to pool data and bioresources to address current gaps in knowledge about AD in DS. All participants will be included after obtaining a written informed consent approved by the ethics committee. A total of 90 DS subjects with AD dementia of both sexes and good general condition will be included. The presence of a family member will be required as well as a sufficient visual and hearing acuity. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sleep Efficiency
The ratio of total sleep time (TST) to time in bed (TIB)
Measured: 4 weeks
Secondary outcomes (1)
The apnea/hypopnea index (AHI)
the sum of all apneas (> 90% reduction in airflow for >10 seconds) and all hypopneas (airflow reduction greater than 30% for at 11 least 10 seconds with an oxygen saturation decrease of approximately 3% or a cortical awakening) per hour of sleep, and mean oxygen saturation during the night (Sp02)
Measured: 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 May 2019
- Study start8 May 2019
- Primary completionMar 2020 (estimated)
- Study completionDec 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimer's DiseaseStudies of the same condition, open and under way.
- More trials run by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03942341
- Sponsor's protocol ID
- IIBSP-ASD-2019-15
- Status last verified
- May 2019
- First submitted
- 2 May 2019
- Last updated
- 10 May 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 May 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Alzheimer's Disease on Sleep in Adults With Down Syndrome
- ClinicalTrials.gov ID
- NCT03942341
- Acronym / sponsor ID
- IIBSP-ASD-2019-15
- Keywords
- Down syndrome, Alzheimer's disease, obstructive sleep apnea, Polysomnography
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauUniversity, hospital or other
- Study start
- 8 May 2019 (actual)
- Primary completion
- Mar 2020 (estimated)
- Study completion
- Dec 2020 (estimated)
- First posted
- 8 May 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE of the project. Adults with Down syndrome (DS) present severe sleep disorders that are under recognized by caregivers. Aging in DS population increases the prevalence of both Obstructive Sleep Apnea (OSA) and Alzheimer´s disease (AD) dementia at much higher rates than in the general population. AD increases the risk of sleep disturbances and OSA, which in turn worsen cognitive performance and behavioral function.
Our hypothesis is that adults with DS and AD dementia will present a higher prevalence of sleep disorders (sleep disruption, sleep circadian disorders and OSA) than in DS without dementia.
There are no data evaluating nocturnal sleep in adults with DS with AD dementia.
The main objective is to evaluate the prevalence of sleep disturbances in adult subjects with DS and AD dementia, by means of subjective and objectives sleep measures.
Detailed description
Aims To characterize and determine the prevalence of sleep disorders and sleep wake pattern in a large community-based sample of adult subjects with DS and AD dementia and to correlate the results with clinical, cognitive and behavioral features.
OBJECTIVES:
The general objective is to evaluate the impact of AD dementia on sleep in adults with DS.
- By evaluating the frequency of sleep problems in demented adults with DS through:
- Nocturnal sleep by polysomnography (PSG)
- Subjective sleep quality (Pittsburg) and daytime Somnolence (Epworth)
- Sleep-wake pattern by actimetry
- By analyzing the association between sleep problems and both age and body mass index (BMI)
- By analyzing the impact of sleep problems on:
- Daytime Somnolence (Epworth, actigraphy)
- Diurnal Behavioural disturbances
- Neurophysiological performance The secondary objective is to compare the sleep data of the DS patients with AD dementia with our sleep data of DS patients without dementia. The project is the continuation of our sleep research work in adults with DS. We have performed a community-based cross-sectional study in 54 adults with DS by means of objective and subjective measures, and we found a high prevalence of sleep disorders (Giménez, 2018). In this study, 6 DS patients had AD dementia. Although the sample was very small, our results show that the symptomatic AD-DS group presented a higher apnea hypopnea index (AHI), higher oxygen desaturations (ODI-3%), and higher respiratory arousal index compared to the non demented DS group. The DS group with dementia had also worse sleep efficiency and higher sleep fragmentation. METHODS: Muliticenter sleep study. Cross-sectional analytical study. The study duration is 24 months. Participants: 90 subjects with DS and AD. Only subjects with mild and moderate mental retardation will be included. Variables and method of collection:
- Neurological evaluation: Standard visit in which medical and neurological past medical history will be reviewed to apply the inclusion and exclusion criteria.
- Neuropsychological evaluation: The neuropsychological battery will be administered by neuropsychologists with experience in the evaluation of DS subjects. The study includes neuropsychological tests that have proven to be sensitive to detect cognitive impairment and is based, in part, from the recommendations of the "Working Group for the Establishment of Criteria for the Diagnosis of Dementia in Individuals with Intellectual Disability." The complete battery has an approximate length of 90 min and consists in:
- Functional, daily living activities and neuropsychiatric scales.
- Estimated Intelligence Quotient (IQ): Kaufman Brief Intelligence Test (K-BIT).
- Global cognition battery adapted to Intellectual Disabilities: CAMDEX-DS, including the structured interview CAMDEX-DS and the cognitive battery CAMCOG-DS.
- Memory: The Cued Recall Test (CRT) adapted version (Deveny, 2002).
- Executive function: Cats and dogs test (adaptation of Day-Night Stroop), to measure inhibition capacity and backward digits.
- Attention: cancellation test.
- Language: semantic fluency test (animals), 30 items from the Boston Naming Test (BNT).
- Sleep evaluation: All participants will undergo a full sleep evaluation. This includes a sleep interview with a sleep specialist, and a subjective and objective evaluation of nocturnal sleep and the circadian sleep-wake pattern. Nocturnal sleep will be objectively studied by full video PSG and Sleep/wake pattern will be collected via sleep diaries and actigraphy. c.1. Objective sleep measures: Polysomnography (PSG). Sleep recordings will be performed in individual, sound-attenuated, temperature-regulated rooms in sleep units in all groups. Participants will be continuously supervised by qualified technical staff and recorded on video/audio with the use of an infrared camera. PSGs will start at their median bedtime as defined by the prospective diary collection, with a recording time of 8 hours. The morning after the PSG nights, all subjects will complete a subjective questionnaire about their sleep quality in the laboratory. We will compare this questionnaire with their usual reported sleep quality at home. All-night video PSG-recordings include: 1) 19 EEG- channels referenced to averaged mastoid electrodes (A1-A2) according to the international 10-20 system; 2) 2 electroculographic channels; and 3) 4 surface electromyographic channels: 2 from the mentalis, one from the right anterior tibialis and one from the left anterior tibialis in lower limbs; and 4) 6 channels to monitor respiratory function: one for oximetry, 2 for oro-nasal airflow using a thermistor and nasal-cannula, 2 to record thoraco-abdominal movements by inductance plethysmography, and a microphone at the suprasternal notch to detect snoring. Sleep stages will be visually scored for 30-s epochs according to the guidelines of the American Academy of Sleep Medicine (AASM). Scoring will be performed by an experienced sleep technologist and later reviewed by an accredited sleep specialist. Arousals will be defined using AASM criteria. Respiratory variables will include the apnea/hypopnea index (AHI), defined as the sum of all apneas (> 90% reduction in airflow for >10 seconds) and all hypopneas (airflow reduction greater than 30% for at 11 least 10 seconds with an oxygen saturation decrease of approximately 3% or a cortical awakening) per hour of sleep, and mean oxygen saturation during the night (Sp02). Periodic leg movements and abnormal REM sleep behavior disorder will be defined according to the International Criteria of Sleep Disorders. c.2. Actigraphy: During the week before the PSG, participants will wear an actigraph in the non-dominant arm, a method of monitoring human rest/activity cycles. Variables obtained by actimetry will be analysed in two groups:
- Activity analysis: variables describing level of activity and light during 24 hours and during all period. Includes average of daily activity during all period, maximum activity times and variance.
- Sleep analysis: to asses sleep variables derived from actigraphy, bedtime and awake time would be need to know from each subject. These information will be collected through event marker system of the actimeter and from sleep diaries recording. c.3. Subjective Sleep Measures (assessed by caregiver): All participants will have a notebook that includes subjective sleep questionnaires and sleep diaries to be completed by the caregivers. Sleep questionnaires will include the following scales: the Pittsburgh Sleep Quality Index (PSQI) to assess patients' self-reports of sleep quality; the Epworth Sleepiness Scale (ESS) to evaluate somnolence (with a modification of the last question about the DS person as a passenger in a car while stopped for a few minutes in traffic); and the Berlin Questionnaire (BQ) to identify subjects at risk for the sleep apnea syndrome Sleep diary is a daily report of sleep and waking activities over 24-hour periods. The sleep diary reports: bedtime, wake time, how much time taken to fall asleep, how much time spent awake after sleep onset. STATISTICAL ANALYSIS: Statistical analyses will be performed using SPSS v23 software. Demographics and sleep scores will be compared between groups by means of t tests. The statistical threshold is set at 0.05. To assess the differences between the various sleep techniques performed in DS participants, general lineal models (GLM) with one within-subject factor (techniques, 3 levels) will be applied separately to each sleep variable. For all variables, results will be pair-compared by means of the t-test. Greenhouse-Geisser correction will be used. The Pearson correlation will be applied to evaluate the relationship between sleep variables. STUDY LIMITATIONS The main foreseen limitation for this study it the heterogeneity of the DS population. To try to overcome this difficulty and to facilitate the feasibility of the study, only subjects with mild or mild-moderate mental retardation will be selected. ETHICAL ISSUES The study will be carried out in strict accordance with international ethical guidelines for medical research in humans. Researchers are responsible for ensuring that the study is conducted in accordance with standards contained in the Declaration of Helsinki and local regulation. All participants will be included after obtaining a written informed consent (the family member's consent will also be obtained). Before including any subject in the study, the investigator will inform the participant of the objectives, methods and potential risks of the study or any inconvenience this may cause. The studies that will be performed in this project are not part of the routine evaluation of subjects with DS and they have an interest only from a research point of view. To preserve the confidentiality of information, data pertaining to this study will not be included in the conventional medical history, but in a separate file in a protected location.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Adult subjects with Down syndrome and Alzheimer Disease | – | –Patients will be included from the 6 centers of the Horizon 21 european consortium. Horizon 21 consortium consists of DS cohorts from Spain (the Down Alzheimer Barcelona Neuroimaging Initiative -DABNI). France (the TriAl 21 at Jérôme Lejeune Institute in Paris), the UK (The LonDowns consortium and Dementia in Down's Syndrome (DiDS) in Cambridge), the Netherlands (the Rotterdam DS cohort) and Germany (AD21 in Munich), with a combined total of more than 1,000 older participants with DS to pool data and bioresources to address current gaps in knowledge about AD in DS. All participants will be included after obtaining a written informed consent approved by the ethics committee. A total of 90 DS subjects with AD dementia of both sexes and good general condition will be included. The presence of a family member will be required as well as a sufficient visual and hearing acuity. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All participants will be included after obtaining a written informed consent approved by the ethics committee. A total of 90 DS subjects with AD dementia of both sexes and good general condition will be included. The presence of a family member will be required as well as a sufficient visual and hearing acuity.
Key inclusion criteria (4 listed)
- Subjects of both sexes with ages over 18 years old with DS.
- Subjects will have to be able to understand and accept the study procedures and sign an informed consent (patient and or guardian).
- Only subjects with mild and moderate mental retardation according to ICD-10criteria (IQ scores> 34).
- Subjects with dementia: subjects with acquired cognitive impairment (assessed by longitudinal neuropsychological tests and/or anamnesis to the family). Absence of comorbid psychiatric disorders (major depressive disorder, bipolar disorder, schizophrenia, autism or behavioral disorders).
Key exclusion criteria (5 listed)
- Don't meet Inclusion Criteria
- Severe mental retardation
- History of conditions that could affect brain structure or function, such as stroke or traumatic brain injury
- Patients in treatment with CPAP
- New psychoactive drugs in the last three months preceding the survey.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Sleep Efficiency
Time frame: 4 weeks
The ratio of total sleep time (TST) to time in bed (TIB)
1 secondary outcome
The apnea/hypopnea index (AHI)
Time frame: 4 weeks
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 May 2019.
Related trials for Alzheimer's Disease
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
RecruitingPhase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Alzheimer's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Alzheimer's Disease and Obstructive Sleep Apnea, run by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 10 May 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sleep Efficiency (time frame: 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 May 2019.